Jessica Tassan
Stock Analyst at Piper Sandler
(0.55)
# 4,278
Out of 4,690 analysts
229
Total ratings
40.6%
Success rate
-2.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Maintained: Buy | $370 → $346 | $278.88 | +24.07% | 7 | Aug 26, 2026 | |
| CVS CVS Health | Maintained: Buy | $99 → $113 | $93.06 | +21.43% | 12 | Aug 26, 2026 | |
| CTEV Claritev | Rated: Buy | $61 → $73 | $39.39 | +85.33% | 11 | Aug 18, 2026 | |
| PRVA Privia Health Group | Maintained: Buy | $36 | $20.79 | +73.16% | 12 | Aug 7, 2026 | |
| DOCS Doximity | Reiterated: Buy | $42 → $47 | $26.73 | +75.83% | 14 | Aug 7, 2026 | |
| OMCL Omnicell | Reiterated: Buy | $49 → $45 | $33.08 | +36.03% | 22 | Aug 3, 2026 | |
| HUM Humana | Upgraded: Buy | $254 → $463 | $385.54 | +20.09% | 8 | Jul 30, 2026 | |
| OSCR Oscar Health | Rated: Buy | $25 → $36 | $30.47 | +18.15% | 9 | Jul 28, 2026 | |
| UNH UnitedHealth Group | Maintained: Buy | $420 → $475 | $392.95 | +20.88% | 20 | Jul 15, 2026 | |
| PHR Phreesia | Downgraded: Hold | $34 → $12 | $12.15 | -1.23% | 16 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 → $2 | $1.59 | +25.79% | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $95 | $87.35 | +8.76% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $13.62 | +120.26% | 14 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $9 | $6.50 | +38.46% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $4.60 | +291.30% | 22 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $8 | $11.93 | n/a | 13 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $10 | $4.90 | n/a | 4 | Jan 17, 2024 |
The Cigna Group
Aug 26, 2026
Maintained: Buy
Price Target: $370 → $346
Current: $278.88
Upside: +24.07%
CVS Health
Aug 26, 2026
Maintained: Buy
Price Target: $99 → $113
Current: $93.06
Upside: +21.43%
Claritev
Aug 18, 2026
Rated: Buy
Price Target: $61 → $73
Current: $39.39
Upside: +85.33%
Privia Health Group
Aug 7, 2026
Maintained: Buy
Price Target: $36
Current: $20.79
Upside: +73.16%
Doximity
Aug 7, 2026
Reiterated: Buy
Price Target: $42 → $47
Current: $26.73
Upside: +75.83%
Omnicell
Aug 3, 2026
Reiterated: Buy
Price Target: $49 → $45
Current: $33.08
Upside: +36.03%
Humana
Jul 30, 2026
Upgraded: Buy
Price Target: $254 → $463
Current: $385.54
Upside: +20.09%
Oscar Health
Jul 28, 2026
Rated: Buy
Price Target: $25 → $36
Current: $30.47
Upside: +18.15%
UnitedHealth Group
Jul 15, 2026
Maintained: Buy
Price Target: $420 → $475
Current: $392.95
Upside: +20.88%
Phreesia
May 28, 2026
Downgraded: Hold
Price Target: $34 → $12
Current: $12.15
Upside: -1.23%
May 12, 2026
Reiterated: Hold
Price Target: $4 → $2
Current: $1.59
Upside: +25.79%
May 6, 2026
Maintained: Buy
Price Target: $60 → $95
Current: $87.35
Upside: +8.76%
Mar 2, 2026
Reiterated: Buy
Price Target: $30
Current: $13.62
Upside: +120.26%
Feb 26, 2026
Reiterated: Buy
Price Target: $12 → $9
Current: $6.50
Upside: +38.46%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $4.60
Upside: +291.30%
May 23, 2025
Reiterated: Hold
Price Target: $10 → $8
Current: $11.93
Upside: n/a
Jan 17, 2024
Maintained: Hold
Price Target: $13 → $10
Current: $4.90
Upside: n/a